ACADIA PHARMACEUTICALS INC — Director's Dealing 2021

Apr 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2021-04-29

Reporting Person: DAVIS STEPHEN (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-29	Common Stock	M	15625	—	Acquired	57162	Direct
2021-04-30	Common Stock	S	7850	$20.33	Disposed	49312	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-29	Restricted Stock Units	$	M	15625	Disposed		Common Stock (15625)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F2: The amount of securities beneficially owned reported in Column 5 above has been adjusted to correct an error in the Reporting Person's prior Form 4 caused by the failure to carry over the correct number of shares from the prior report. The number of shares owned prior to the transactions reported herein was 41,537 shares.

F3: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F4: The restricted stock units vest in four equal annual installments beginning 4/29/2020.